Sangamo Therapeutics, Inc. is a US-based clinical-stage genomic medicine firm that aims to develop transformative medicines for patients and their families suffering from serious diseases. The company's clinical-stage products include ST-920, a gene therapy candidate for treating Fabry disease, TX200, a chimeric antigen receptor engineered regulatory T cell therapy candidate for preventing immune-mediated rejection in HLA-A2 mismatched kidney transplantation, SB-525, a gene therapy candidate being trialed in phase 3 for treating moderately severe to severe haemophilia A, and BIVV003, a zinc finger nuclease gene-edited cell therapy candidate being trialed in Phase 1/2 PRECIZN-1 study for treating sickle cell disease. Their preclinical development focus is on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has formed collaborative and strategic partnerships with several industry leaders like Biogen MA, Kite Pharma, Pfizer Inc., Sanofi S.A., Novartis Institutes for BioMedical Research, Shire International GmbH, Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech Inc., Open Monoclonal Technology Inc., F. Hoffmann-La Roche Ltd, Hoffmann-La Roche Inc., and California Institute for Regenerative Medicine. The California-based company, which was previously known as Sangamo BioSciences, changed its name to Sangamo Therapeutics, Inc. in January 2017.
Sangamo Therapeutics's ticker is SGMO
The company's shares trade on the NASDAQ stock exchange
They are based in Brisbane, California
There are 51-200 employees working at Sangamo Therapeutics
It is sangamo.com
Sangamo Therapeutics is in the Healthcare sector
Sangamo Therapeutics is in the Biotechnology industry
The following five companies are Sangamo Therapeutics's industry peers: